Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.

Human Pathology

Volumn 38, Issue 3, 2007, Pages 462-467

  Witkiewicz, Agnieszka ^a   Raghunath, Puthiyaveettil ^b   Wasik, Agnieszka ^c   Junkins Hopkins, Jacqueline M ^b   Jones, Dan ^d   Zhang, Qian ^b   Odum, Niels ^e,f   Wasik, Mariusz A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cutaneous T cell lymphoma; DNMT1 DNA methyltransferase; SHP 1 tyrosine phosphatase; STAT3 transcription factor

Indexed keywords

DNA METHYLTRANSFERASE 1; FORMALDEHYDE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SKIN BIOPSY;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; SHP1 PROTEIN TYROSINE PHOSPHATASE; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 33846865591     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.09.012     Document Type: Article

References (20)

1. Kazakov D.V., Burg G., and Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 18 (2004) 397-415
2. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., and Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (2003) 857-866
3. Weinstock M.A., and Gardstein B. Twenty year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 89 (1999) 1240-1244
4. Zhang Q., Raghunath P.N., Vonderheid E., Odum N., and Wasik M.A. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 57 (2000) 1137-1146
5. Zhang Q., Wang H.Y., Marzec M., Raghunath P.N., Nagasawa T., and Wasik M.A. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A 102 (2005) 6948-6953
6. Zhang Q., Wang H.Y., Woetmann A., Raghunath P.N., Ødum N., and Wasik M.A. STAT3 induces transcription of the DNA methyltransferase 1 (DNMT1) gene in malignant T lymphocytes. Blood 108 (2006) 1058-1064
7. Lefeber W.P., Robinson J.K., Clendenning W.E., Dunn J.L., and Colton T. Attempts to enhance light microscopic diagnosis of cutaneous T-cell lymphoma (mycosis fungoides). Arch Dermatol 117 (1981) 408-411
8. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
9. Rawlings J.S., Rosler K.M., and Harrison D.A. The JAK/STAT signaling pathway. J Cell Sci 117 (2004) 1281-1283
10. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
11. Nielsen M., Kaltoft K., Nordahl M., et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A 94 (1997) 6764-6769
12. Robertson K.D. DNA methylation and chromatin-unraveling the tangled web. Oncogene 21 (2002) 5361-5379
13. Mena-Duran A.V., Togo S.H., Bazhenova L., et al. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br J Haematol 129 (2005) 791-794
14. Sommer V.H., Clemmensen O.J., Nielsen O., et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18 (2004) 1288-1295
15. Claus R., Almstedt M., and Lubbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol 32 (2005) 511-520
16. Jing N., Zhu Q., Yuan P., Li Y., Mao L., and Tweardy D.J. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 5 (2006) 279-286
17. Weisenberger D.J., Velicescu M., Cheng J.C., Gonzales F.A., Liang G., and Jones P.A. Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2 (2004) 62-72
18. Stewart D.J., Donehower R.C., Eisenhauer E.A., et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 14 (2003) 766-774
19. Turkson J., Zhang S., Palmer J., et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3 (2004) 1533-1542
20. Ulane C.M., Rodriguez J.J., Parisien J.P., and Horvath C.M. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 77 (2003) 6385-6393